RECORD // Company

Cabaletta Bio, Inc.

Built 2026-11-22T00:40:27Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Cabaletta Bio · Ctgov · exact name match to 'Cabaletta Bio, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001759138-26-000047

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-53,053,0003 months ended 2026-09-3010-Q2026-11-050001759138-26-0000472026-11-22 00:40 UTCReport an error
Interest expense$511,0003 months ended 2026-09-3010-Q2026-11-050001759138-26-0000472026-11-22 00:40 UTCReport an error
Cash and cash equivalents$299,383,000at 2026-09-3010-Q2026-11-050001759138-26-0000472026-11-22 00:40 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001759138
Ticker
CABA
CUSIP
12674W109
Record ID
sx:sec:0001759138

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Business address2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 191042026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-167,856,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:40 UTCReport an error
Total assets (at 2025-12-31)$165,083,0002025-12-3110-K, XBRL Assets2026-11-22 00:40 UTCReport an error
Stockholders' equity (at 2025-12-31)$112,051,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:40 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$82,982,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:40 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-131,080,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:40 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,229,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:40 UTCReport an error
Form D total offering amount (D filed 2019-01-14)Indefinite2019-01-14D2026-11-22 00:40 UTCReport an error
Form D total amount sold (D filed 2019-01-14)$49,999,9982019-01-14D2026-11-22 00:40 UTCReport an error
Form D industry groupBiotechnology2019-01-14D2026-11-22 00:40 UTCReport an error
Form D revenue rangeDecline to Disclose2019-01-14D2026-11-22 00:40 UTCReport an error
Form D date of first sale2019-01-022019-01-14D2026-11-22 00:40 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)On November 9, 2026, Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) issued a press release presenting new rese-cel (resecabtagene autoleucel, formerly known as CABA-201) Phase 1/2 clinical data featuring immunomodulator-free durability and a favorable benefit-risk profile across autoimmune diseases (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…2026-11-09SEC EDGAR 8-K 0001759138-26-000050 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-09)On November 9, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. Cabaletta is presenting new rese-cel (resecabtagene autoleucel, formerly known as CABA-201) Phase 1/2 clinical data featuring immunomodulator-free durability and a favorable benefit-risk profile across autoimmune diseases in one oral and two poster presentations at the American College of Rheumatology ("ACR") Convergence 2026. Cabaletta’s presentations highlight…2026-11-09SEC EDGAR 8-K 0001759138-26-000050 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…2026-11-05SEC EDGAR 8-K 0001759138-26-000046 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-14)In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of its common stock and an expiration date of September 12, 2026 (the “Expiration Date”). From issuance through June 30, 2026, 5,275,100 Common Stock Warrants were exercised resulting in aggregate gross proceeds of approximately $13.2 million. From July 1, 2026 through the Expiration Date, 46,011,900 Common Stock Warrants were exercised resulting in aggregate gross proceeds of approximately $115.0 million. The aggregate gross proceeds from exercises of the…2026-09-14SEC EDGAR 8-K 0001759138-26-000041 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-13)On August 13, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be…2026-08-13SEC EDGAR 8-K 0001759138-26-000038 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
Largest institutional holder #1 (13F as filed): JENNISON ASSOCIATES LLC$62,304,9002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #2 (13F as filed): Bain Capital Life Sciences Investors, LLC$53,620,8942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$33,447,1212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #4 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C.$28,533,4972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$24,380,2392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$22,476,0262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #7 (13F as filed): Cormorant Asset Management, LP$15,550,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #8 (13F as filed): Woodline Partners LP$13,062,4422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #9 (13F as filed): NORGES BANK$12,789,5672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #10 (13F as filed): Opaleye Management Inc.$12,016,4182026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.